YOLFTbeta
Upstream Bio, Inc.

Upstream Bio, Inc.

UPB · NASDAQ · Healthcare / Biotechnology

2.78USD-0.08 (-2.80%)

Price History

Full chart

Market Stats

Previous Close2.86
Open2.86
Day Range2.73 – 2.98
52-Week Range4.99 – 33.68
Volume891.33K
Market Cap290.29M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.88
Dividend Yield0.00%
50-Day Avg6.38
200-Day Avg12.28

About

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. E. Rand Sutherland M.D., M.P.H.
  • Employees75
  • Headquarters890 Winter Street, Waltham, MA, United States, 02451, USA
  • Websitehttps://upstreambio.com

Leadership

  • Dr. E. Rand Sutherland M.D., M.P.H.CEO & Director · b. 1970
  • Mr. Michael Paul Gray CPA, MBACFO & COO · b. 1971
  • Mr. Aaron Deykin M.D.Chief Medical Officer and Head of Research & Development · b. 1967
  • Ms. Stacy Price M.S., P.M.P.Chief Technology Officer · b. 1969
  • Meggan BuckwellDirector of Corporate Communications & Investor Relations
  • Ms. Allison C. Ambrose J.D.Senior VP, General Counsel & Secretary · b. 1985
  • Ms. Lisa FieringSenior Vice President of People & Culture
  • Dr. Adam Houghton M.B.A., Ph.D.Chief Business Officer · b. 1971
  • Ms. Mersedeh Miraliakbari Pharm.D.Senior Vice President of Regulatory Affairs & Quality
  • Ms. Fang Xie Ph.D.VP & Head of Biometrics

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue1.21M2.38M2.37M2.85M
Growth (%)-+96.37%-0.42%+20.42%
Cost of Revenue7.00K60.00K89.00K188.00K
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.00%100.00%100.00%100.00%
Operating Expense25.12M42.49M80.13M163.22M
Operating Income-23.91M-40.11M-77.76M-160.36M
Operating Margin-1972.69%-1685.46%-3281.18%-5618.82%
EBITDA-23.86M-20.48M-62.72M-143.25M
EBITDA Margin-1968.73%-860.38%-2646.29%-5019.45%
Net Income-23.87M-20.54M-62.81M-143.44M
Net Income Margin-1969.31%-862.90%-2650.04%-5026.03%
R&D18.66M31.80M62.97M136.81M
R&D as % of Total Revenue1539.36%1336.09%2656.79%4793.48%

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets18.48M117.20M481.72M353.77M
Total Liabilities124.63M240.32M11.87M14.00M
Total Equity-106.16M-123.13M469.85M339.77M
Cash17.05M25.83M325.89M101.58M
Total Debt94.00K45.00K1.83M1.27M
Net Debt-16.96M-25.79M-324.06M-100.31M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-19.02M-37.93M-59.17M-133.28M
Investing Cash Flow-82.00K-82.84M-59.48M-93.48M
Financing Cash Flow9.96M129.55M418.91M2.44M
Capital Expenditure82.00K144.00K511.00K165.00K
Free Cash Flow-19.10M-38.07M-59.68M-133.28M
FCF to OCF100.43%100.38%100.86%100.00%

Earnings

Report DateAug 28, 2024Nov 7, 2024Mar 12, 2025May 6, 2025Aug 6, 2025Nov 5, 2025Mar 24, 2026May 13, 2026Aug 11, 2026Nov 4, 2026
EPS Estimate0.00-3.65-0.54-0.48-0.61-0.78-0.70-0.75-0.78-0.67
EPS Actual-11.18-6.96-0.41-0.51-0.74-0.63-0.78-0.75-0.73-
Surprise--90.68%24.12%-6.25%-21.31%19.23%-11.43%0.00%6.41%-
Timing-Pre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap290.29M
Enterprise Value25.00M
Trailing P/E0.00
Forward P/E0.00
Price / Sales91.92
Price / Book1.05
EPS-2.88
Book Value4.95
Revenue (TTM)3.16M
Gross Profit (TTM)3.16M
EBITDA-169.78M
Profit Margin0.00%
Operating Margin-5480.98%
Return on Equity-46.05%
Return on Assets-30.28%
Shares Outstanding54.77M
Shares Float42.81M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 31.14
  • Strong Buy
    2
  • Buy
    2

Ownership Breakdown

Institutions
92.45%
Insiders
14.78%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    8.10M14.79%
  • Orbimed Advisors LLC
    5.69M10.40%
  • NORGES BANK
    3.77M6.88%
  • BlackRock Inc
    3.37M6.15%
  • Decheng Capital LLC
    2.72M4.97%
  • Enavate Sciences GP, LLC
    2.46M4.49%
  • Vanguard Capital Management, LLC
    1.87M3.42%
  • Millennium Management LLC
    1.14M2.09%
  • D. E. Shaw & Co LP
    1.04M1.89%
  • Geode Capital Management, LLC
    950.62K1.74%
  • Parkman Healthcare Partners LLC
    935.25K1.71%
  • SEB Asset Management AB
    878.47K1.60%
  • Bain Capital Life Sciences Investors, LLC
    867.21K1.58%
  • Woodline Partners LP
    831.48K1.52%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.44M2.63%
  • Fidelity Small Cap Growth
    1.37M2.50%
  • Fidelity Stock Selector Small Cap
    1.32M2.41%
  • Fidelity Series Small Cap Opps
    965.80K1.76%
  • iShares Russell 2000 ETF
    907.20K1.66%
  • SEB Läkemedelsfond A (SEK)
    878.47K1.60%